Expert panel reviews emergency use application for Sputnik V vaccine; seeks immunogenicity, safety data

Dr Reddy's Laboratories on February 19 said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for the Russian vaccine.

Published: 24th February 2021 10:35 PM  |   Last Updated: 25th February 2021 01:57 AM   |  A+A-

Sputnik V, Russia covid-19 vaccine,

Sputnik V vaccine (File photo| AP)


NEW DELHI: Looking into an application for emergency use authorisation in India for the Russia-made Sputnik V COVID-19 vaccine, an expert panel of the country's Central Drug Authority on Wednesday asked Dr Reddy's Laboratories, the Indian manufacturer of the vaccine, to provide some additional details including immunogenicity and safety data, sources said.

On February 19, Dr Reddy's Laboratories said it had approached drugs regulator DCGI for emergency use authorisation (EUA) for the Russian vaccine.

"The Subject Expert Committee (SEC) on COVID-19 of the CDSCO, which discussed the application by Dr Reddy's Laboratories seeking emergency use authorisation for COVID-19 vaccine Sputnik V, on Wednesday asked the firm to submit immunogenicity and safety data in accordance with the protocol approved by the CDSCO. Once it submits the data, its EUA application will be considered," a source said.

The drug major presented the safety profile of the phase 2 study and the interim data of the phase 3 trial on Wednesday, the source said.

ALSO READ | Credibility of made-in-India vaccines evident in their high demand: Prasad

Meanwhile, the SEC also asked Hyderabad-based Bharat Biotech to submit the efficacy data of Covaxin on adults before seeking permission to conduct the phase-3 clinical trial on children aged 5-18 years.

In September last year, Hyderabad-based Dr Reddy's Laboratories partnered with the Russian Direct Investment Fund (RDIF) to conduct the clinical trials of Sputnik V and for its distribution rights in India.

The vaccine is undergoing the phase 3 clinical trial in India.

The Drugs Controller General of India (DCGI) has already given the EUA nod for two COVID-19 vaccines -- Covaxin of Bharat Biotech and Covishield of Oxford-AstraZeneca, being manufactured by the Serum Institute of India in Pune.

The vaccines are being administered to healthcare and frontline workers across the country.

Sputnik V has demonstrated an efficacy rate of 91.6 per cent in the interim analysis of its phase 3 clinical trial, which includes data on 19,866 volunteers in Russia, the statement said.

The vaccine also maintained a consistent efficacy at 91.8 per cent even among the group of 2,144 volunteers over 60 years of age.

ALSO READ | Mutants different from variants, COVID appropriate behaviour vital to stop spread: Scientists

"The efficacy of Sputnik V was reported to be 91.6 per cent by the Lancet, which is an impressive development in the fight against COVID-19. The initiation of the EUA process will be a critical step forward for us in ensuring speedy access to the Sputnik V vaccine in India," Dr Reddy's Laboratories co-chairman and managing director G V Prasad said.

Sputnik V, developed by the Gamaleya National Research Institute of Epidemiology and Microbiology, was registered by the Ministry of Health of Russia on August 11, 2020 and became the world's first registered vaccine against COVID-19 based on the human adenoviral vector platform.

Sputnik V has already received approval in 26 countries and has been administered to more than 20 lakh people worldwide.


Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on are those of the comment writers alone. They do not represent the views or opinions of or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp